Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
12.60
-0.01 (-0.08%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
3
4
5
6
Next >
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
December 06, 2022
From
Singapore Economic Development Board (EDB)A*STAR
Via
ACN Newswire
Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration
November 22, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US
November 17, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies
November 11, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Delivers Strong FY2022 H1 Results and Raises Full-Year Forecast
October 27, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy
October 20, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
October 14, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
October 05, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,...
Via
FinancialNewsMedia
Topics
Cannabis
Exposures
Cannabis
U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Use of TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
October 05, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Strengthening Healthcare Systems to Meet Patients’ Need for Plasma-Derived Therapies
September 29, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewable Energy Production in the United States
September 19, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies
September 16, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Selects New Partners for Global Corporate Social Responsibility (CSR) Program to Strengthen Health Systems in Low- and Middle-Income Countries
September 13, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure
August 22, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Delivers Strong First Quarter FY2022 Results; On Track Towards Full-Year Management Guidance
July 28, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease
July 26, 2022
Palm Beach, FL – July 26, 2022 – FinancialNewsMedia.com News Commentary – As COVID-19 vaccines for kids achieve the Centers for Disease Control and Prevention (CDC) recommendation, concern it could...
Via
FinancialNewsMedia
Exposures
COVID-19
Product Safety
Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
July 21, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces the Submission of its Corporate Governance Report to the Tokyo Stock Exchange
July 11, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
June 30, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
June 27, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts
June 22, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
As Health Problems Mount Patients Welcome New Treatments
June 14, 2022
Palm Beach, FL – June 14, 2022 – FinancialNewsMedia.com News Commentary – There are several serious health problems facing society today. Some, like heart disease, gastrointestinal diseases, cancer,...
Via
FinancialNewsMedia
Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial
June 09, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA
May 31, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna
May 31, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna
May 31, 2022
Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for SpikevaxTM from August 1,...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
May 26, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022
May 11, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories
April 26, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay
April 22, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.